Psoriasis pill tested for rare muscle disease
NCT ID NCT07012057
Summary
This study aimed to test if an oral medication called deucravacitinib, already approved for plaque psoriasis, could help adults with dermatomyositis or juvenile dermatomyositis who did not respond well to standard treatments. Participants would have taken the pill twice daily for 24 weeks while attending regular clinic visits to monitor their muscle strength, skin symptoms, and safety. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.